Aura Biosciences wins FDA nod for light-activated ocular melanoma treatment

Aura Biosciences said today that the FDA approved its Investigational New Drug Application for the company’s light-activated viral nanoparticle conjugates for the treatment of ocular melanoma.

The federal watchdog’s approval allows Cambridge, Mass.-based Aura to move forward with initial clinical tests of AU-011. The Phase Ib open-label clinical trial, which is currently enrolling, is designed to evaluate the safety, immunogenicity and preliminary efficacy of 2 dose levels of AU-011 for the treatment of small-to-medium primary ocular melanoma, according to Aura.

Get the full story at our sister site, Drug Delivery Business News.

The post Aura Biosciences wins FDA nod for light-activated ocular melanoma treatment appeared first on MassDevice.

from MassDevice http://ift.tt/2jU5O0K